Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Stocks Crossing The 13 Week Moving Average <$10.01 -- Ignore unavailable to you. Want to Upgrade?

To: James Strauss who wrote (2980)	11/4/1998 12:29:00 AM
From: flickerful	Read Replies (1) \| Respond to of 13094

TRMS.....EWH jim. TRMS. last night i read press releases from TRMS regarding their T-20, and i was fortunate enough to trade it today successfully. but, its ascension to 13 status carries with it the unmistakable imprint of a meteoric rise... having closed monday at 4 7/8, it opened today at 8, reached as high as 10 3/4, and finally closed at 9. for what its worth.... also, see article below* EWH are you very familiar with WEBs? ( web equity baskets...) thanks, randy ps FOUR published a solid annual report & appears to be holding its own. Trimeris Announces Publication of Phase I/II Clinical Trial Results of T-20, A Novel HIV Drug DURHAM, N.C.--(BUSINESS WIRE)--Nov. 3, 1998-- First in New Class of Drugs Shows Potency and Safety Trimeris, Inc. (NASDAQ: TRMS) announced today publication of Phase I/II clinical trial results of T-20 in the November issue of Nature Medicine. As a fusion inhibitor, T-20 is the first of a new class of anti-HIV drugs that block the entry of the virus into cells. T-20 produces a potent antiviral effect even in HIV-infected subjects who have been treated with other anti-viral agents. The article was a collaboration among the University of Alabama at Birmingham, Duke University, and Trimeris, Inc. The authors note that the short-term potency of T-20, when given alone, reduces viral load at a rate comparable to current 3 and 4 drug combination regimens of reverse transcriptase inhibitors and protease inhibitors. In the Phase I/II clinical trial, T-20 was administered for fourteen days to 16 HIV infected adults, including some with prior antiretroviral treatment. "T-20 was safely dosed in all patients with no serious toxicities. We were pleased to find that patients in the highest dose group experienced profound reductions of viral load even though T-20 was the only anti-HIV drug they were receiving during the study period," stated Dr. Michael Kilby the principal investigator for the study at UAB. "The results of the first T-20 clinical trial are important as we look forward to the future treatment of HIV/AIDS," stated Dr. Joseph Eron, a leading HIV researcher from the University of North Carolina at Chapel Hill. "There is an increasing pool of HIV infected patients who are beginning to become non-responsive to currently available treatments. As one looks at the drug development pipeline, T-20 is the only drug in Phase II clinical trials that attacks HIV by a different mechanism of action. This means that T-20 should be effective against the emerging multiple drug resistant virus that is increasingly difficult to treat." The Company's current Phase II clinical trial, TRI-003, is designed to define the optimal dose(s), compare the effectiveness of continuous infusion versus intermittent injection, and provide additional data regarding the effect of T-20 on viral load. Results from TRI-003 are expected to be reported in early 1999. These data will provide a basis for initiating pivotal clinical trials during 1999.